Floatz logo

Vibecotamab

B-Cell Acute Lymphoblastic Leukemia

Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Vibecotamab is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
53 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →